If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 231 - 240 of 284

A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS with IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)

This project is being done to learn more about Luspatercept if administrated at the maximum approved starting dose to assess that a quicker benefit can be seen in your transfusion burden and hemoglobin level.

Protocol No
BMS-CA0561060

An Open-Label, Multi-Center, Single-Arm Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

This project is being done to evaluate the safety and tolerability of glofitamab-polatuzumab-R-CHP in patients newly diagnosed DLBCL and determine if a blood test that measures MRD can identify patients most likely to benefit from this regimen.
Protocol No
DFCI-22-606